New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium

References

• Al Omari AA, Al Omari MM, Badwan AA, Al-Sou’od KA. 2011. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state. J Pharm Biomed Anal. 54(3):503–509.
   PubMed Web of Science ®Google Scholar
• Al-Obaidi H, Buckton G. 2009. Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. AAPS PharmSciTech. 10(4):1172–1177.
   PubMed Web of Science ®Google Scholar
• Alonzo DE, Zhang GGZ, Zhou D, Gao Y, Taylor LS. 2010. Understanding the behavior of amorphous pharmaceutical systems during dissolution. Pharm Res. 27(4):608–618.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 12(3):413–420.
   PubMed Web of Science ®Google Scholar
• Anderson BD. 2018. Predicting solubility/miscibility in amorphous dispersions: it is time to move beyond regular solution theories. J Pharm Sci. 107(1):24–33.
   PubMed Web of Science ®Google Scholar
• Artusio F, Pisano R. 2018. Surface-induced crystallization of pharmaceuticals and biopharmaceuticals: a review. Int J Pharm. 547(1–2):190–208.
   PubMed Web of Science ®Google Scholar
• Ashland Inc. 2016. AquaSolve – physical and chemical properties handbook. Covington: Ashland.
   Google Scholar
• Baghel S, Cathcart H, O'Reilly NJ. 2016. Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 105(9):2527–2544.
   PubMed Web of Science ®Google Scholar
• Baghel S, Cathcart H, O’Reilly NJ. 2016. Theoretical and experimental investigation of drug–polymer interaction and miscibility and its impact on drug supersaturation in aqueous medium. Eur J Pharm Biopharm. 107:16–31.
   PubMed Web of Science ®Google Scholar
• Barbosa LCA. 2007. Espectroscopia no infravermelho na caracterização de compostos orgânicos. Viçosa: UFV.
   Google Scholar
• Barreras A, Gurk-Turner C. 2003. Angiotensin II receptor blockers. Bumc Proc. 16:123–126.
   Google Scholar
• Bevernage J, Brouwers J, Brewster ME, Augustijns P. 2013. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 453(1):25–35.
   PubMed Web of Science ®Google Scholar
• Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 59(7):617–630.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. 2009. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 98(8):2549–2572.
   PubMed Web of Science ®Google Scholar
• Darwhekar GN, Jain DK, Chouhan J. 2012. Biopharmaceutical classification of candesartan and candesartan cilexetil. Asian J Pharm Life Sci. 2:295–302.
   Google Scholar
• Descamps M, Willart JF. 2016. Perspectives on the amorphisation/milling relationship in pharmaceutical materials. Adv Drug Deliv Rev. 100:51–66.
   PubMed Web of Science ®Google Scholar
• Detroja C. 2011. Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: formulation, characterization and pharmacodynamic study. Sci Pharm. 79(3):635–651.
   PubMedGoogle Scholar
• Gao P, Shi Y. 2012. Characterization of supersaturatable formulations for improved absorption of poorly soluble drugs. AAPS J. 14(4):703–713.
   PubMed Web of Science ®Google Scholar
• Geçer A, Yıldız N, Çalımlı A, Turan B. 2010. Trimethyl chitosan nanoparticles enhances dissolution of the poorly water soluble drug candesartan cilexetil. Macromol Res. 18(10):986–991.
   Web of Science ®Google Scholar
• Guo Y, Shalaev E, Smith S. 2013. Physical stability of pharmaceutical formulations: solid-state characterization of amorphous dispersions. TrAC – Trends Anal Chem. 49:137–144.
   Web of Science ®Google Scholar
• Gurunath S, Nanjwade BK, Patila PA. 2014. Enhanced solubility and intestinal absorption of candesartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J. 22(3):246–257.
   PubMed Web of Science ®Google Scholar
• He Y, Ho C. 2015. Amorphous solid dispersions: utilization and challenges in drug discovery and development. J Pharm Sci. 104(10):3237–3258.
   PubMed Web of Science ®Google Scholar
• Hemmelgarn BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan N, Campbell N. 2008. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol. 24(6):507–512.
   PubMed Web of Science ®Google Scholar
• Holm R, Müllertz A, Mu H. 2013. Bile salts and their importance for drug absorption. Int J Pharm. 453(1):44–55.
   PubMed Web of Science ®Google Scholar
• Husain A, Azim S, Mitra M, Bhasin PS, Husain A, Azim S. 2011. A Review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci. 1:12–17.
   Google Scholar
• Kaur N, Narang A, Bansal AK. 2018. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption. Eur J Pharm Biopharm. 129:222–246.
   PubMed Web of Science ®Google Scholar
• Kleberg K, Jacobsen J, Müllertz A. 2010. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol. 62(11):1656–1668.
   PubMed Web of Science ®Google Scholar
• Klein S. 2010. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 12(3):397–406.
   PubMed Web of Science ®Google Scholar
• Kovalski V, Prestes AP, Oliveira JG, Alves GF, Colarites DF, Mattos JE, Sordi R, Vellosa JC, Fernandes D. 2017. Protective role of cGMP in early sepsis. Eur J Pharmacol. 807:174–181.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Löbmann K, Strachan CJ, Grohganz H, Rades T. 2013. Emerging trends in the stabilization of amorphous drugs. Int J Pharm. 453(1):65–79.
   PubMed Web of Science ®Google Scholar
• Loh ZH, Samanta AK, Sia Heng PW. 2015. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci. 10(4):255–274.
   Web of Science ®Google Scholar
• Lu E, Li S, Wang Z. 2017. Biorelevant test for supersaturable formulation. Asian J Pharm Sci. 12(1):9–20.
   PubMed Web of Science ®Google Scholar
• Mahesh RD, Umang KG, Dhaval DM, Kalpesh AP, Manek R, Navin S. 2015. Formulation, optimization and characterization of candesartan cilexetil nanosuspension for in vitro dissolution enhancement. Afr J Pharm Pharmacol. 9(5):102–113.
   Google Scholar
• Matsunaga H, Eguchi T, Nishijima K, Enomoto T, Sasaoki K, Nakamura N. 1999. Solid-state characterization of candesartan cilexetil (TCV-116): crystal structure and molecular mobility. Chem Pharm Bull (Tokyo). 47:182–186.
   Web of Science ®Google Scholar
• Meng F, Dave V, Chauhan H. 2015. Qualitative and quantitative methods to determine miscibility in amorphous drug–polymer systems. Eur J Pharm Sci. 77:106–111.
   PubMed Web of Science ®Google Scholar
• Nart V, França MT, Anzilaggo D, Riekes MK, Kratz JM, De Campos CEM, Simões CMO, Stulzer HK. 2015. Ball-milled solid dispersions of BCS Class IV drugs: impact on the dissolution rate and intestinal permeability of acyclovir. Mater Sci Eng C. 53:229–238.
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Karatgi P, Prabhu R, Pillai R. 2010. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech. 11(1):9–17.
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T. 2009. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol. 14(3):290–298.
   PubMed Web of Science ®Google Scholar
• Pinto JMO, Leão AF, Riekes MK, França MT, Stulzer HK. 2018. HPMCAS as an effective precipitation inhibitor in amorphous solid dispersions of the poorly soluble drug candesartan cilexetil. Carbohydr Polym. 184:199–206.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen Y, Zhang GG, Yu L, Mantri RV. 2017. Developing solid oral dosage forms. Cambridge: Academic Press.
   Google Scholar
• Satturwar P, Eddine MN, Ravenelle F, Leroux J-C. 2007. pH-responsive polymeric micelles of poly(ethylene glycol)-b-poly(alkyl(meth)acrylate-co-methacrylic acid): influence of the copolymer composition on self-assembling properties and release of candesartan cilexetil. Eur J Pharm Biopharm. 65(3):379–387.
   PubMed Web of Science ®Google Scholar
• Sayyad FJ, Tulsankar SL, Kolap UB. 2013. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. J Pharm Res. 7:381–388.
   Google Scholar
• Schmieder RE. 2005. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens. 18(5):720–730.
   PubMed Web of Science ®Google Scholar
• Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. 2014. Amorphous solid dispersions. New York (NY): Springer New York.
   Google Scholar
• Surampalli G, Nanjwade BK, Patil PA, Chilla R. 2014. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation. Drug Deliv. 23:2124–2138.
   PubMed Web of Science ®Google Scholar
• Tanno F, Nishiyama Y, Kokubo H, Obara S. 2004. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm. 30(1):9–17.
   PubMed Web of Science ®Google Scholar
• Thakral S, Terban MW, Thakral NK, Suryanarayanan R. 2016. Recent advances in the characterization of amorphous pharmaceuticals by X-ray diffractometry. Adv Drug Deliv Rev. 100:183–193.
   PubMed Web of Science ®Google Scholar
• USP. 2016. The United States Pharmacopeia. 39th ed. Rockville: United States Pharmacopeial Convention.
   Google Scholar
• Van Eerdenbrugh B, Baird JA, Taylor LS. 2010. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation – classification and comparison with crystallization tendency from undercooled melts. J Pharm Sci. 99(9):3826–3838.
   PubMed Web of Science ®Google Scholar
• Vasconcelos T, Marques S, das Neves J, Sarmento B. 2016. Amorphous solid dispersions: rational selection of a manufacturing process. Adv Drug Deliv Rev. 100:85–101.
   PubMed Web of Science ®Google Scholar
• Volpe M, Gallo G, Tocci G. 2018. Is early and fast blood pressure control important in hypertension management? Int J Cardiol. 254:328–332.
   PubMed Web of Science ®Google Scholar
• Warren DB, Benameur H, Porter CJH, Pouton CW. 2010. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 18(10):704–731.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter C. 2013. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 65(1):315–499.
   PubMed Web of Science ®Google Scholar
• Yuce M, Guven O, Karahan S, Saracbasi O, Capan Y. 2016. Preformulation of immediate release candesartan cilexetil tablets using full factorial experimental design. Lat Am J Pharm. 35:921–930.
   Web of Science ®Google Scholar
• Zhou L, Chen X, Gu Y, Liang J. 2009. Transport characteristics of candesartan in human intestinal Caco-2 cell line. Biopharm Drug Dispos. 30(5):259–264.
   PubMed Web of Science ®Google Scholar